Relistor generic?

What Generic Relistor Options Are Available?

Relistor is a medication used to treat opioid-induced constipation, commonly experienced by patients receiving opioid pain relief. The generic version of Relistor contains methylnaltrexone, a synthetic opioid receptor antagonist.

When Does the Exclusivity Expire?

The patent for Relistor's original formulation is held by US WorldMeds, a subsidiary of Adamas Pharmaceuticals. According to DrugPatentWatch.com [1], the patent for the original Relistor formulation (methylnaltrexone bromide) is set to expire on September 23, 2030.

Have Biosimilars Been Approved?

As of our knowledge cutoff, no biosimilars for Relistor have been approved by the FDA. However, several biosimilar candidates are currently undergoing clinical trials and review processes.

Comparison with Other Products

Relistor's active ingredient, methylnaltrexone, is also available under the brand name Relistor as a subcutaneous injection. Other products containing methylnaltrexone include Rhythm Pharmaceuticals' Methylnaltrexone. Additionally, some medications, such as naloxegol (Movantik), also address opioid-induced constipation, although their mechanisms and dosing may differ.

Pricing and Availability

Generic versions of Relistor have not yet entered the market due to patent restrictions. Prices for Relistor brand medication vary depending on location, insurance, and availability. It is essential for patients to consult with their healthcare provider or pharmacist for the most current pricing and availability information.

Sources:

[1] DrugPatentWatch.com: Methylnaltrexone Bromide Patent Expiration

List of Sources:

1. DrugPatentWatch.com: Methylnaltrexone Bromide Patent Expiration